Ellis Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Ellis Investment Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-400	Closed	-$3K	–	688
2022 Q3	$3K	Hold	400	–	–	﹤0.01%	711
2022 Q2	$3K	Hold	400	–	–	﹤0.01%	714
2022 Q1	$3K	Hold	400	–	–	﹤0.01%	736
2021 Q4	$3K	Hold	400	–	–	﹤0.01%	735
2021 Q3	$3K	Buy	400 +53	+15%	+$496	﹤0.01%	719
2021 Q2	$3K	Sell	347 -1	-0.3%	-$11	﹤0.01%	723
2021 Q1	$4K	Hold	348	–	–	﹤0.01%	688
2020 Q4	$3K	Buy	348 +1	+0.3%	+$10	﹤0.01%	672
2020 Q3	$3K	Buy	347 +100	+40%	+$1.06K	﹤0.01%	666
2020 Q2	$2K	Hold	247	–	–	﹤0.01%	675
2020 Q1	$2K	Hold	247	–	–	﹤0.01%	655
2019 Q4	$2K	Hold	247	–	–	﹤0.01%	647
2019 Q3	$1K	Hold	247	–	–	﹤0.01%	683
2019 Q2	$2K	Buy	+247	New	+$2.98K	﹤0.01%	623

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Ellis Investment Partners's TEVA Position: Q4 2022 in Review

Ellis Investment Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2022, closing a stake of 400 shares — an estimated $3K sold.

Ellis Investment Partners first reported a position in TEVA in Q2 2019 and held it in 14 quarters. The position peaked at $4K in Q1 2021. 422 funds tracked by Wall St. Rank hold TEVA as of Q4 2022.

Ellis Investment Partners reported no remaining Teva Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Ellis Investment Partners sold 400 Teva Pharmaceuticals shares in Q4 2022, an estimated $3K.
Ellis Investment Partners first reported a position in Teva Pharmaceuticals in Q2 2019 and held it in 14 quarters.
Ellis Investment Partners's Teva Pharmaceuticals position peaked at $4K in Q1 2021.
422 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.